AR119207A1 - DERIVADOS DE PIRROLO[1,2-c]IMIDAZOL COMO INHIBIDORES DE EGFR - Google Patents

DERIVADOS DE PIRROLO[1,2-c]IMIDAZOL COMO INHIBIDORES DE EGFR

Info

Publication number
AR119207A1
AR119207A1 ARP200101746A ARP200101746A AR119207A1 AR 119207 A1 AR119207 A1 AR 119207A1 AR P200101746 A ARP200101746 A AR P200101746A AR P200101746 A ARP200101746 A AR P200101746A AR 119207 A1 AR119207 A1 AR 119207A1
Authority
AR
Argentina
Prior art keywords
pyrrolo
imidazole derivatives
egfr inhibitors
egfr
imidazole
Prior art date
Application number
ARP200101746A
Other languages
English (en)
Inventor
Cosimo Dolente
Annick Goergler
David Stephen Hewings
Georg Jaeschke
Bernd Kuhn
Yvonne Alice Nagel
Roger David Norcross
Christa Ulrike Obst-Sander
Antonio Ricci
Daniel Rueher
Sandra Steiner
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR119207A1 publication Critical patent/AR119207A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Steroid Compounds (AREA)

Abstract

Compuestos derivados de pirrolo[1,2-c]imidazol con actividad inhibitoria alostérica de EGFR, composición farmacéutica que los comprende y su uso en el tratamiento del cáncer de pulmón de células pequeñas. Reivindicación 1: Un compuesto de fórmula (1) o sales farmacéuticamente aceptables.
ARP200101746A 2019-06-21 2020-06-19 DERIVADOS DE PIRROLO[1,2-c]IMIDAZOL COMO INHIBIDORES DE EGFR AR119207A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP19181772 2019-06-21

Publications (1)

Publication Number Publication Date
AR119207A1 true AR119207A1 (es) 2021-12-01

Family

ID=67001684

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP200101744A AR121167A1 (es) 2019-06-21 2020-06-19 DERIVADOS DE PIRROLO[1,2-c]IMIDAZOL COMO INHIBIDORES DE EGFR
ARP200101746A AR119207A1 (es) 2019-06-21 2020-06-19 DERIVADOS DE PIRROLO[1,2-c]IMIDAZOL COMO INHIBIDORES DE EGFR

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ARP200101744A AR121167A1 (es) 2019-06-21 2020-06-19 DERIVADOS DE PIRROLO[1,2-c]IMIDAZOL COMO INHIBIDORES DE EGFR

Country Status (19)

Country Link
US (2) US20220315591A1 (es)
EP (2) EP3986567B1 (es)
JP (2) JP2022537771A (es)
KR (1) KR20220024096A (es)
CN (2) CN113993590A (es)
AR (2) AR121167A1 (es)
AU (1) AU2020296933A1 (es)
BR (1) BR112021024810A2 (es)
CA (1) CA3139171A1 (es)
CL (1) CL2021003373A1 (es)
CO (1) CO2021016967A2 (es)
CR (1) CR20210614A (es)
IL (1) IL287806A (es)
MA (1) MA56507A (es)
MX (1) MX2021015889A (es)
PE (1) PE20220807A1 (es)
TW (2) TW202115070A (es)
WO (2) WO2020254547A1 (es)
ZA (1) ZA202108775B (es)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2307365B1 (en) 2008-06-25 2013-03-27 Merck Sharp & Dohme Corp. Synthesis and use of heterocyclic antibacterial agents
US8420661B2 (en) 2010-04-13 2013-04-16 Hoffmann-La Roche Inc. Arylethynyl derivatives
WO2016183534A1 (en) 2015-05-14 2016-11-17 The Wistar Institute Of Anatomy And Biology Ebna1 inhibitors and methods using same
US10385019B2 (en) * 2015-06-30 2019-08-20 Dana-Farber Cancer Institute, Inc. Inhibitors of EGFR and methods of use thereof
AR113299A1 (es) * 2017-06-02 2020-04-08 Hoffmann La Roche Compuestos de isoindolina
CR20200625A (es) * 2018-06-29 2021-02-05 Hoffmann La Roche Compuestos

Also Published As

Publication number Publication date
EP3986566B1 (en) 2023-08-30
BR112021024810A2 (pt) 2022-01-25
MX2021015889A (es) 2022-02-03
WO2020254546A1 (en) 2020-12-24
AR121167A1 (es) 2022-04-27
IL287806A (en) 2022-01-01
CN113993591A (zh) 2022-01-28
TW202115073A (zh) 2021-04-16
KR20220024096A (ko) 2022-03-03
CR20210614A (es) 2022-02-11
AU2020296933A1 (en) 2021-12-02
WO2020254547A1 (en) 2020-12-24
EP3986566C0 (en) 2023-08-30
EP3986566A1 (en) 2022-04-27
ZA202108775B (en) 2022-09-28
TW202115070A (zh) 2021-04-16
EP3986567C0 (en) 2023-08-30
CO2021016967A2 (es) 2022-01-17
EP3986567A1 (en) 2022-04-27
US20220315591A1 (en) 2022-10-06
PE20220807A1 (es) 2022-05-20
JP2022537772A (ja) 2022-08-29
CA3139171A1 (en) 2020-12-24
JP2022537771A (ja) 2022-08-29
CN113993590A (zh) 2022-01-28
CL2021003373A1 (es) 2022-10-07
US20220112199A1 (en) 2022-04-14
MA56507A (fr) 2022-04-27
EP3986567B1 (en) 2023-08-30

Similar Documents

Publication Publication Date Title
CO2022001357A2 (es) Inhibidores de shp2 fosfatasa de tipo pirazolo[3,4-b]pirazina
PH12020551717A1 (en) Dual atm and dna-pk inhibitors for use in anti-tumor therapy
CL2019000941A1 (es) Compuestos de pirazolo[1,5-a]piridina sustituidos como inhibidores de la quinasa ret.
NI201000004A (es) Derivados de pirimidina trisustituida para el tratamiento de enfermedades proliferativas.
NI201000003A (es) Derivados de pirimidina trisustituida para el tratamiento de enfermedades proliferativas.
BR112015022993A8 (pt) inibidores de jak2 e alk2 e métodos para sua utilização.
BR112021019643A2 (pt) Compostos de pirazolopiridina como inibidores do ret e uso dos mesmos
BR112017017135A2 (pt) inibidores de tgf-beta
ECSP11011113A (es) Piridiloxi-indoles inhibidores del vegf-r2 y uso de los mismos para el tratamiento de enfermedades
ECSP10010419A (es) Derivados heterocíclicos de urea y métodos de uso de los mismos-211
ECSP109935A (es) Derivados de morfolino pirimidina utilizados en enfermedades relacionadas con mtor quinasa y/o pi3k
CO2021009879A2 (es) Inhibidores aza-heterobicíclicos de mat2a y métodos de uso para tratar el cáncer
UY30298A1 (es) Inhibidores de la quinasa c-fms ii
MX2021010321A (es) Compuestos macrociclicos.
DOP2019000184A (es) Inhibidores selectivos de jak1
MX2022002219A (es) Triazolopirimidinas como inhibidores de a2a/a2b.
CL2019001694A1 (es) Compuestos de pirazolopirimidina y métodos de uso de los mismos.
EP4327877A3 (en) Dual atm and dna-pk inhibitors for use in anti-tumor therapy
CR20210456A (es) Pirazolopiridinas y triazolopiridinas como inhibidores de a2a / a2b
AR119206A1 (es) DERIVADOS DE PIRROLO[1,2-c]IMIDAZOL COMO INHIBIDORES DE EGFR
AR119207A1 (es) DERIVADOS DE PIRROLO[1,2-c]IMIDAZOL COMO INHIBIDORES DE EGFR
ZA202201499B (en) Dual atm and dna-pk inhibitors for use in anti-tumor therapy
MX2021012499A (es) Inhibidores mejorados del complejo de activación transcripcional notch y métodos para el uso de estos.
EA202092016A1 (ru) Имидазопиримидины и триазолопиримидины в качестве ингибиторов a2a/a2b
BR112021019629A2 (pt) Derivado de espiro que contém nitrogênio como inibidor de ret